Rocket Pharmaceuticals said it received $180 million by selling an FDA drug review priority review voucher tied to the accelerated approval of Kresladi in March for a pediatric rare disease. The company positioned the proceeds as non-dilutive capital to advance its gene therapy program for Danon disease, which is described as in pivotal clinical testing. The priority review voucher structure converts a regulatory milestone into cash to fund pipeline development. Rocket emphasized that voucher-driven financing is being used to support the next stage of its late-development asset rather than offseting near-term operating costs. The announcement links FDA’s rare disease review mechanisms directly to late-stage execution, reinforcing how regulatory designations can translate into sizable balance-sheet support for smaller biotech firms.